SARS-CoV-2

[Proceedings of the National Academy of Sciences of the United States of America] Researchers found that, in contrast to current convention, “immunodominant” SARS-CoV-2 peptides defined by in silico methods often failed to elicit T cell responses recognizing naturally presented SARS-CoV-2 epitopes.

[Annals of Neurology] Cerebrospinal fluid was assessed between day 1-30, between day 31-90, or later than 90 days of COVID-19 diagnosis.

[Science Advances] Scientists used the high-density microarray patch to deliver a SARS-CoV-2 spike subunit vaccine directly to the skin.

[Lancet Global Health] The authors assessed the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists expressed two neutralizing monoclonal antibodies (Abs) against SARS-CoV-2; H4 and B38 in three formats: IgG1, IgA1 monomers, and IgA1 dimers in glycoengineered Nicotiana benthamiana plants.

[Nature Communications] Scientists examined potential confounders in COVID-19 respiratory microbiome studies by analyzing the upper and lower respiratory tract microbiome in well-phenotyped COVID-19 patients and controls combining microbiome sequencing, viral load determination, and immunoprofiling.